医学と薬学 78/8 2021年8月号

出版社: 自然科学社
発行日: 2021-07-27
分野: 薬学  >  雑誌
ISSN: 03893898
雑誌名:
特集: 川崎病―基礎と臨床の最前線
電子書籍版: 2021-07-27 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

2,200 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

目次

  • 特集 川崎病―基礎と臨床の最前線

    序文
    川崎病の疫学―近年の動向
    川崎病の遺伝要因
    川崎病血管炎の動物モデル
    川崎病の病理アップデート―心血管病変を中心に
    川崎病診断の手引き改訂6版―改訂のねらい
    川崎病急性期治療のガイドライン―改訂のポイント
    2020年改訂版 川崎病心臓血管後遺症の診断と治療に関するガイドライン―改訂のポイント コロナウイルス感染症と川崎病

    Diagnosis
     WesTMを用いた自動ウエスタンブロットによる
      橋本脳症の診断バイオマーカー(抗NAE抗体)の測定系開発

    Health Care
     バサルトストーントリートメントによる身体・肌への影響に関する検証試験

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 川崎病 - 基礎と臨床の最前線】

P.916 掲載の参考文献
1) 川崎富作 : 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群 : 自験例50例の臨床的観察. アレルギー 16 : 178-222, 1967.
2) 川崎病全国調査担当グループ : 第25回川崎病全国調査成績. https://www.jichi.ac.jp/dph/wp-dph/wp-content/uploads/2020/09/e2e27b17833a88e-36bf2008d23c9e385.pdf
3) Kobayashi T, Ayusawa M, Suzuki H, et al : Revision of diagnostic guidelines for Kawasaki disease. Pediatr Int 62 : 1135-1138, 2020.
4) 小佐見光樹, 屋代真弓, 牧野伸子, 他 : 第25回川崎病全国調査成績. 小児科診療 83 : 269-273, 2020.
5) Ae R, Makino N, Kosami K, et al : Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease : The nationwide survey in Japan, 2017-2018. J Pediatr 225 : 23-29.e2, 2020.
6) Nakamura Y, Yashiro M, Yamashita M, et al : Cumulative incidence of Kawasaki disease in Japan. Pediatr Int 60 : 19-22, 2018.
7) Sano T, Makino N, Aoyama Y, et al : Temporal and geographical clustering of Kawasaki disease in Japan : 2007-2012. Pediatr Int 58 : 1140-1145, 2016.
8) Fujita Y, Nakamura Y, Sakata K, et al : Kawasaki disease in families. Pediatrics 84 : 666-669, 1989.
9) Uehara R, Yashiro M, Nakamura Y, et al : Parents with history of Kawasaki disease whose child also had the same disease. Pediatr Int 53 : 511-514, 2011.
10) Sudo D, Nakamura Y : Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. Acta Paediatr 106 : 796-800, 2017.
11) Sudo D, Makino N, Nakamura Y : Recurrent Kawasaki disease and cardiac complications : nationwide surveys in Japan. Arch Dis Child 105 : 848-852, 2020.
12) Makino N, Nakamura Y, Yashiro M, et al : Epidemiological observations of Kawasaki disease in Japan, 2013-2014. Pediatr Int 60 : 581-587, 2018.
13) Goto T, Sano T, Kojo T, et al : Time course of cardiac lesions due to Kawasaki disease in Japan : 22nd nationwide survey (2011-2012). Pediatr Int 58 : 1274-1276, 2016.
14) Kuwabara M, Yashiro M, Kotani K, et al : Cardiac lesions and initial laboratory data in Kawasaki disease : a nationwide survey in Japan. J Epidemiol 25 : 189-193, 2015.
15) Ae R, Abrams JY, Maddox RA, et al : Platelet count variation and risk for coronary artery abnormalities in Kawasaki disease. Pediatr Infect Dis J 30 : 197-203, 2020.
16) Nakamura Y, Aso E, Yashiro M, et al : Mortality among Japanese with a history of Kawasaki disease : results at the end of 2009. J Epidemiol 23 : 429-434, 2013.
17) Ae R, Abrams JY, Maddox RA, et al : Corticosteroids added to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in high-risk patients with Kawasaki Disease. J Am Heart Assoc 9 : e015308, 2020.
P.922 掲載の参考文献
1) Onouchi Y : Molecular Genetics of Kawasaki disease. Pediatric Res 65 : 46R-54R, 2009.
2) Onouchi Y, Tamari M, Takahashi A, et al : A genomewide linkage analysis of Kawasaki disease : evidence for linkage to chromosome 12. J Hum Genet 52 : 179-190, 2007.
3) Onouchi Y, Gunji T, Burns JC, et al : ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 40 : 35-42, 2008.
4) Onouchi Y, Ozaki K, Burns JC, et al : Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 19 : 2898-2906, 2010.
5) Onouchi Y, Fukazawa R, Yamamura K, et al : Variations in ORAI1 Gene Associated with Kawasaki Disease. PLoS One 11 : e0145486, 2016.
6) Khor CC, Davila S, Breunis WB, et al : Genomewide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 43 : 1241-1246, 2011.
7) Onouchi Y, Ozaki K, Burns JC, et al : A genomewide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44 : 517-521, 2012.
8) Lee YC, Kuo HC, Chang JS, et al : Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet 44 : 522-525, 2012.
9) Johnson TA, Mashimo Y, Wu JY, et al : Association of an IGHV3-66 gene variant with Kawasaki disease. J Hum Genet 66 : 475-489, 2021.
10) Onouchi Y, Suzuki Y, Suzuki H, et al : ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 13 : 52-59, 2013.
11) Thiha K, Mashimo Y, Suzuki H, et al : Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease. J Hum Genet 64 : 511-519, 2019.
12) Suzuki H, Terai M, Hamada H, et al : Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 30 : 871-876, 2011.
13) Hamada H, Suzuki H, Onouchi Y, et al : Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA) : a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 393 : 1128-1137, 2019.
14) 三浦大, 鮎澤衛, 伊藤秀一, 他 : 日本小児循環器学会川崎病急性期治療のガイドライン (2020年改訂版). 日本小児循環器学会雑誌 36 (Suppl 1) : 1-29, 2020.
P.929 掲載の参考文献
1) Murata H : Experimental Candida-induced arteritis in mice. Relation to arteritis in the mucocutaneous lymph node syndrome. Microbiol Immunol 23 : 825-831, 1979.
2) Lehman TJA, Walker SM, McCurdy D, et al : Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum 28 : 652-659, 1985.
3) Nishio H, Sueishi K, Hara T, et al : Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vasc Biol 31 : 1093-1099, 2011.
4) 村田久雄 : 川崎病の実験モデル. 日本臨床 41 : 2075-2079, 1983.
5) Ohno N : chemistry and biology of angitis inducer, Candida albicans water-soluble mannoprotein-beta-glucan complex (CAWS). Microbiol Immunol 47 : 479-490, 2003.
6) Tanaka H, Yanai C, Ohno N, et al : Coronary vasculitis induced in mice by cell wall mannoprotein fractions of clinically isolated Candida species. Med Mycol J 61 : 33-48, 2020.
7) Takahashi K. Oharaseki T, Naoe S, et al : Histopathological features of murine systemic vasculitis caused by Candida albicans extract-an animal model of Kawasaki disease-. Inflamm Res 53 : 72-77, 2004.
8) Nagi-Miura N, Oharaseki T, Ohno N, et al : Induction of coronary arteritis with administration of CAWS (Candida albicans water-soluble fraction) depending on mouse strain. Immunopharmacol Immunotoxicol 26 : 527-543, 2004.
9) Oharaseki T, Kameoka Y, Naoe S, et al : Susceptibilitiy loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans-derived substances. Microbiol Immunol 49 : 181-189, 2005.
10) Tada R, Miura N, Ohno N, et al : The influence of culture conditions on vasculitis and anaphylactoid shock induced by fungal pathogen Candida albicans cell wall extract in mice. Microb Pathog 44 : 379-388, 2008.
11) Hirata N, Ishibashi K, Ohno N, et al : β-mannosyl linkages inhibit CAWS arteritis by negatively regulating dectin-2-dependent signaling in spleen and dendritic cells. Immunopharmacol Immunotoxicol 35 : 594-604, 2013.
12) Oharaseki T, Yokouchi Y, Takahashi K, et al : Recognition of alpha-mannan by dectin 2 is essential for onset of Kawasaki disease-like murine vasculitis induced by Candida albicans cell-wall polysaccharide. Mod Rheumatol 30 : 350-357, 2020.
13) Miyabe C, Miyabe Y, Bricio-Moreno L, et al : Dectin-2-induced CCL2 production in tissue-resident macrophages ignites cardiac arteritis. J Clin Invest 129 : 3610-3624, 2019.
14) Takahashi K, Oharaseki T, Suzuki K, et al : Administraion of human immunoglobulin suppresses development of murine systemic vasculitis induced with Candida albicans water-soluble fraction : an animal model of Kawasaki disease. Mod Rheumatol 20 : 160-167, 2010.
15) Oharaseki T, Kameoka Y, Suzuki K, et al : Administration of recombinant single chain fragment of variable region (hScFv) of IGG suppresses development of murine vasculitis induced with Candida albicans water-soluble fraction : An animal model of Kawasaki disease. ADC Letter for Infectious Disease Control 6 : 51-55, 2019.
16) Oharaseki T, Mamada H, Takahashi K, et al : The role of TNF-α in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod Rheumatol 24 : 120-128, 2014.
17) Rosenkranz ME, Schulte DJ, Arditi M : TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in mouse of Kawasaki disease. Circulation 112 : 2966-2973, 2005.
18) Hui-Yuen JS, Duong TT, Yeung RS : TNF-alpha is necessary for induction of coronary inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 176 : 6294-6301, 2006.
19) Lee Y, Schulte DJ, Arditi M, et al : Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 125 : 1542-1550, 2012.
20) Motomura Y, Kanno S, Asano K, et al : Identification of pathogenic cardiac CD11c+ macrophages in Nod1-mediated acute coronary arteritis. Arterioscler Thromb Vasc Biol 35 : 1423-1433, 2015.
P.937 掲載の参考文献
1) Naoe S, Takahashi K, Masuda H, et al : Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn 41 (11) : 785-797, 1991.
2) Takahashi K, Oharaseki T, Yokouchi Y : Histopathological aspects of cardiovascular lesions in Kawasaki disease. Int J Rheum Dis 21 (1) : 31-35, 2018.
3) Takahashi K, Oharaseki T, Naoe S, et al : Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 47 (3) : 305-310, 2005.
4) 増田弘毅, 神田実喜男, 直江史郎, 他 : 川崎病 (MCLS) における冠状動脈瘤と他の冠状動脈瘤との関連性. 脈管学 23 (2) : 135-145, 1983.
5) 濱島義博 : 川崎病. 日本病理学会会誌 66 : 59-92, 1977.
6) Takahashi K, Oharaseki T, Yokouchi Y, et al : A half-century of autopsy results-incidence of pediatric vasculitis syndromes, especially Kawasaki disease. Circ J 76 (4) : 964-970, 2012.
7) 高橋啓, 直江史郎 : 川崎病冠状動脈瘤血栓性閉塞後の再疎通血管における病理組織学的検討. 日本小児循環器学会誌 10 : 223-240, 1994.
8) 浅地聡, 渋谷宏行, 増田弘毅, 他 : 川崎病における腎病変の病理形態学的研究 冠状動脈病変との関連を考慮して. 脈管学 29 (6) : 453-460, 1989.
9) Sato W, Yokouchi Y, Oharaseki T, et al : The pathology of Kawasaki disease aortitis : a study of 37 cases. Cardiovasc Pathol 51 : 107303, 2020.
10) 渋谷和俊, 跡部俊彦, 増田弘毅, 他 : 川崎病における肺血管病変の病理組織学的研究. 脈管学 27 (4) : 293-304, 1987.
11) Fujiwara H, Hamashima Y : Pathology of the heart in Kawasaki disease. Periatrics 61 (1) : 100-107, 1978.
12) Amano S, Hazama F, Hamashima Y : Pathology of Kawasaki disease : I Pathology and morphologenesis of the vascular changes. Japanese Circulation J 43 (7) : 633-643, 1979.
13) Harada M, Yokouchi Y, Oharaseki T, et al : Histopathological characteristics of myocarditis in acute-phase Kawasaki disease. Histopathology 61 (6) : 1156-1167, 2012.
14) 菅原敏明 : 小児皮膚疾患に対する免疫病理学的アプローチ 川崎病皮膚病変の免疫組織学的検討. 日本小児皮膚科学会雑誌 13 (2) : 107-112, 1994.
15) 渡邊愛子, 藤原碧, 猿喰浩子 : 乾癬様皮疹を呈した川崎病. 皮膚病診療 40 (12) : 1207-1210, 2018.
16) 鈴木祥子, 古賀文二, 今福信一 : 乾癬様の臨床像を呈した川崎病. 皮膚病診療 39 (5) : 507-510, 2017.
17) Yokouchi Y, Oharaseki T, Harada M, et al : Histopathological study of lymph node lesions in the acute phase of Kawasaki disease. Histopathology 62 (3) : 387-396, 2013.
P.944 掲載の参考文献
1) 日本川崎病学会, 特定非営利活動法人日本川崎病研究センター, 厚生労働科学研究 難治性血管炎に関する調査研究班 : 川崎病診断の手引き 改訂第6版. http://www.jskd.jp/info/pdf/tebiki201906.pdf (2021年6月12日アクセス)
2) 柳川 洋 : 川崎病の実態. 公衆衛生情報 5 (12) 別冊 : 22-29, 1975. https://www.jichi.ac.jp/dph/kawasakibyou/report/report1-3.pdf (2021年6月12日アクセス)
3) Newburger JW, Takahashi M, Beiser AS, et al : A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 (23) : 1633-1639, 1991.
4) 特定非営利活動法人日本川崎病研究センター, 川崎病全国調査担当グループ : 第25回川崎病全国調査成績 (2021年6月12日アクセス)
5) 日本循環器学会/日本心臓血管外科学会合同ガイドライン : 2020年改訂版 川崎病心臓血管後遺症の診断と治療に関するガイドライン, 2020.
6) Kondo E, Tanaka T, Nakano T, et al : Cellulitis caused by Streptococcus pyogenes at the Bacille Calmette-Guerin vaccination site : A case report. Kawasaki Medical Journal 44 (1) : 27-31, 2018.
7) Kakisaka Y, Ohara T, Katayama S, et al : Human Herpes Virus Type 6 Can Cause Skin Lesions at the BCG Inoculation Site Similar to Kawasaki Disease. Tohoku J Exp Med 228 (4) : 351-353, 2012.
8) Lai CC, Lee PC, Wang CC, et al : Reaction at the Bacillus-Calmette-Guerin inoculation site in patients with Kawasaki disease. Pediatr Neonatol 54 (1) : 43-48, 2013.
9) Lin MT, Wang JK, Yeh JI, et al : Clinical Implication of the C Allele of the ITPKC Gene SNP rs28493229 in Kawasaki Disease : Association With Disease Susceptibility and BCG Scar Reactivation. Pediatr Infect Dis J 30 (2) : 148-152, 2011.
10) Garrido-Garcia LM, Moguel AC, Rivera MV, et al : Reaction of the BCG Scar in the Acute Phase of Kawasaki Disease in Mexican Children. Pediatr Infect Dis J 36 (10) : e237-e241, 2017.
11) Diniz LMO, Castanheira RG, Giampietro YG, et al : Diagnostic value of the reaction at the Bacillus Calmette- Guerin vaccination site in Kawasaki Disease. Rev Paul Pediatr 39 : e2019338, 2021.
12) 福田清香, 今野裕章, 松本峻, 他 : 川崎病診断の手引き改訂 (第6版) が診断に及ぼす影響. 日本小児科学会雑誌 124 (10) : 1484-1489, 2020.
13) McCrindle BW, Rowley AH, Newburger JW, et al : Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease : A Scientific Statement for Health Professionals from the American Heart Association. Circulation 135 (17) : e927-e999, 2017.
14) Dionne A, Meloche-Dumas L, Desjardins L, et al : N-terminal pro-B-type natriuretic peptide diagnostic algorithm versus American Heart Association algorithm for Kawasaki disease. Pediatr Int 59 (3) : 265-270, 2017.
16) McGahan JP, Phillips HE, Cox KL : Sonography of the normal pediatric gallbladder and biliary tract. Radiology 144 (4) : 873-875, 1982.
17) Kanegaye JT, Van Cott E, Tremoulet AH, et al : Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease. J Pediatr 162 (6) : 1259-1263, 1263.e1-2, 2013.
18) Yanagi S, Nomura Y, Masuda K, et al : Early diagnosis of Kawasaki disease in patients with cervical lymphadenopathy. Pediatr Int 50 (2) : 179-183, 2008.
19) 日本川崎病学会編 : 川崎病診断の手引きガイドブック 2020, 診断と治療社, 東京, 2020.
P.952 掲載の参考文献
1) 佐地勉, 薗部友良, 上村茂, 他 : 川崎病急性期治療のガイドライン. 日本小児循環器学会雑誌 20 (1) : 54-62, 2003
2) Kobayashi T, Inoue Y, Takeuchi K, et al : Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113 (22) : 2606-2612, 2006.
3) Egami K, Muta H, Ishii M, et al : Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149 (2) : 237-240, 2006.
4) Sano T, Kurotobi S, Matsuzaki K, et al : Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166 (2) : 131-137, 2007.
5) Kobayashi T, Saji T, Otani T, et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoints trial. Lancet 379 (9826) : 1613-1620, 2012.
6) Ogata S, Ogihara Y, Honda T, et al : Corticosteroid pulse combination therapy for refractory Kawasaki disease : A randomized trial. Pediatrics 129 (1) : e17-e23, 2012.
7) 佐地勉, 鮎澤衛, 三浦大, 他 : 川崎病急性期治療のガイドライン (平成24年改訂版). 日本小児循環器学会雑誌 28 (s3) : s1-s28, 2012.
8) 日本川崎病研究センター川崎病全国調査担当グループ : 第25回川崎病全国調査成績. https://www.jichi.ac.jp/dph/wp-dph/wp-content/uploads/2019/09/1bb34be7b6c9f852c1df45cc2ac4152c-1.pdf (2021年5月現在)
9) Miyata K, Kaneko T, Morikawa Y, et al : Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE) : a multicentre, prospective cohort study. Lancet Child Adolesc Health 2 (12) : 855-862, 2018.
10) Mori M, Hara T, Kikuchi M, et al : Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease : a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep 8 (1) : 1994, 2018.
11) Tremoulet AH, Jain S, Jaggi P, et al : Infliximab for intensification of primary therapy for Kawasaki disease : a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383 (9930) : 1731-1738, 2014.
12) Hamada H, Suzuki H, Onouchi Y, et al : Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA) : a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 393 (10176) : 1128-1137, 2019.
13) 三浦大, 鮎澤衛, 伊藤秀一, 他 : 川崎病急性期治療のガイドライン (2020年改訂版). 日本小児循環器学会雑誌 36 (s1) : s1.1-s1.29, 2020.
14) Miura M, Kobayashi T, Igarashi T, et al : Realworld safety and effectiveness of infliximab in pediatric patients with acute Kawasaki disease : a post-marketing surveillance in Japan (SAKURA Study). Pediatr Infect Dis J 39 (1) : 41-47, 2020.
15) Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, et al : Kawasaki disease shock syndrome : unique and severe subtype of Kawasaki disease. Pediatr Int 60 (9) : 781-790, 2018.
16) Hoste L, Paemel RV, Haerynck F, et al : Multisystem inflammatory syndrome in children related to COVID-19 : a systematic review. Eur J Pediatr 2021 (in press).
17) Baba T, Maruyama T, Katsuragi S, et al : Multi-system inflammatory syndrome associated with SARS-CoV-2 in a Japanese girl. Pediatr Int 2021 (in press).
18) McCrindle BW, Rowley AH, Newburger JW, et al : Diagnosis, treatment, and long-term management of Kawasaki disease ; a scientific statement for health professionals from the American Heart Association. Circulation 135 (17) : e927-e999, 2017.
19) de Graeff N, Groot N, Ozen S, et al : European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease-the SHARE initiative. Rheumatology 58 (4) : 672-682, 2019.
20) 細川静雄, 原信田実 : 川崎病は, いま-聞き書き 川崎富作. 木魂社, 東京, 2006.
P.960 掲載の参考文献
1) 日本循環器学会, 他 学術委員会合同研究班 : 2020年改訂版 川崎病心臓血管後遺症の診断と治療に関するガイドライン. https://wwwj-circorjp/cms/wp-content/uploads/2020/02/JCS2020_Fukazawa_Kobayashipdf (2021年5月21日アクセス)
2) Kato H, Sugimura T, Akagi T, et al : Long-term Consequences of Kawasaki Disease : A 10- to 21-Year Follow-up Study of 594 Patients. Circulation 94 : 1379-1385, 1996.
3) Miura M, Kobayashi T, Kaneko T, et al : Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events. JAMA Pediatr 172 : e180030, 2018.
4) Suzuki A, Miyagawa-Tomita S, Komatsu K, et al : Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease : immunohistochemical study. Circulation 101 : 2935-2941, 2000.
5) Fukazawa R, Ikegam E, Watanabe M, et al : Coronary artery aneurysm induced by Kawasaki disease in children show features typical senescence. Circ J 71 : 709-715, 2007.
6) Fukazawa R, Kobayashi T, Mikami M, et al : Nationwide Survey of Patients With Giant Coronary Aneurysm Secondary to Kawasaki Disease 1999-2010 in Japan. Circ J 82 : 239-246, 2017.
7) Schmidt-Lucke C, Fichtlscherer S, Rossig L, et al : Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 211 : 249-254, 2010.
8) de Jongh S, Lilien MR, op't Roodt J, et al : Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40 : 2117-2121, 2002.
9) Gupta KK, Ali S, Sanghera RS : Pharmacological Options in Atherosclerosis : A Review of the Existing Evidence. Cardiol Ther 8 : 5-20, 2019.
10) Brasier AR : Vascular Inflammation and the Renin-Angiotensin System. Arterioscler Thromb Vasc Biol 22 : 1257-1266, 2002.
11) 三谷義英 : 移行医療. 日本川崎病学会 編, 川崎病学, pp.205-209, 診断と治療社, 東京, 2018.
P.966 掲載の参考文献
1) 川崎富作 : 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群 (自験例50例の臨床的観察). アレルギー 16 (3) : 178-222, 1967.
2) Lai MMC, Holmes KV : Coronaviridae : the viruses and their replication. In : Knipe D, Howley P, eds. Fields Virology, 4th ed., pp.1163-1186, Lippincott Williams & Wilkins, London, 2001.
3) Peiris JS, Yuen KY, Osterhaus AD, et al : The severe acute respiratory syndrome. N Engl J Med 349 (25) : 2431-2441, 2003.
4) Esper F, Shapiro ED, Weibel C, et al : Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 191 (4) : 499-502, 2005.
5) Esper F, Weibel C, Ferguson D, et al : Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 191 (4) : 492-498, 2005.
6) McIntosh K : Coronaviruses in the limelight. J Infect Dis 191 (4) : 489-491, 2005.
7) Rowley AH, Shulman ST, Garcia FL, et al : Cloning the arterial IgA antibody response during 8386-8391, 2005.
8) Lehmann C, Klar R, Lindner J, et al : Kawasaki Disease Lacks Association With Human Coronavirus NL63 and Human Bocavirus. Pediatr Infect Dis J 28 (6) : 553-554, 2009.
9) Baker SC, Shimizu C, Shike H, et al : Human coronavirus-NL63 infection is not associated with acute Kawasaki disease Adv Exp Med Biol 581 : 523-526, 2006.
10) Rubens JH, Akindele NP, Tschudy MM, et al : Acute covid-19 and multisystem inflammatory syndrome in children. BMJ 372 : n385, 2021.
11) Shields K, Atlas K, Farber JS, et al : Multisystem Inflammatory Syndrome in Children : A Review. Am J Nurs 121 (5) : 26-37, 2021.
12) Iannarella R, Lattanzi C, Cannata G, et al : Coronavirus infections in children : from SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features. Acta Biomed 91 (3) : e2020032, 2021.
13) Martins MM, Prata-Barbosa A, da Cunha AJLA : Update on SARS-CoV-2 infection in children. Paediatr Int Child Health 41 (1) : 56-64, 2021.
14) Kwak JH, Lee SY, Choi JW et al : Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Clin Exp Pediatr 64 (2) : 68-75, 2021.
15) Rafferty MS, Burrows H, Joseph JP, et al : Multisystem inflammatory syndrome in children (MIS-C) and the coronavirus pandemic : Current knowledge and implications for public health. J Infect Public Health 14 (4) : 484-494, 2021.
16) 賀籐均 : 新型コロナウイルス感染症とMultisystem Inflammatory Syndrome in Children. 小児内科 53 (1) : 147-149, 2021.
17) Sancho-Shimizu V, Brodin P, Cobat A, et al : SARS-CoV-2-related MIS-C : A key to the viral and genetic causes of Kawasaki disease? J Exp Med 218 (6) : e20210446, 2021.
18) Consiglio CR, Cotugno N, Sardh F, et al : The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell 183 (4) : 968-981.e7, 2020.
19) Suzuki J, Abe K, Matsui T, et al : Kawasaki Disease Shock Syndrome in Japan and Comparison With Multisystem Inflammatory Syndrome in Children in European countries. Front Pediatr 9 : 625456, 2021.
20) Noval Rivas M, Porritt RA, Cheng MH, et al : COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) : A novel disease that mimics toxic shock syndrome-the superantigen hypothesis J Allergy Clin Immunol 147 (1) : 57-59, 2021.
21) Pouletty M, Borocco C, Ouldali N, et al : Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19) : a multicentre cohort. Ann Rheum Dis 79 (8) : 999-1006, 2020.
22) Toubiana J, Poirault C, Corsia A, et al : Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France : prospective observational study. BMJ 369 : m2094, 2020.
23) Whittaker E, Bamford A, Kenny J, et al : Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 324 (3) : 259-269, 2020.
24) Chen MR, Kuo HC, Lee YJ, et al : Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Front Immunol 12 : 632890, 2021.
25) Gruber CN, Patel RS, Trachtman R, et al : Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell 183 (4) : 982-995.e14, 2020.
26) Porritt RA, Paschold L, Noval Rivas M, et al : HLA class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children. J Clin Invest 131 (10) : e146614, 2021.
27) Porritt RA, Paschold L, Rivas MN, et al : Identification of a unique TCR repertoire, consistent with a superantigen selection process in Children with Multi-system Inflammatory Syndrome. bioRxiv : 2020.11.09.372169, 2020
28) Cheng MH, Porritt RA, Rivas MN, et al : A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. bioRxiv : 2020.11.24.395079, 2020.
29) Kouo T, Chaisawangwong W : SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children (MIS-C). J Clin Invest 131 (10) : e149327, 2021.
30) Suenaga T, Suzuki H, Shibuta S, et al : Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr 55 (2) : 266-270, 2009
31) Leung DYM, Schlievert PM : Kawasaki syndrome : role of superantigens revisited. FEBS J 288 (6) : 1771-1777, 2021.

【Diagnosis】

P.976 掲載の参考文献
1) 森昌朋 : 特集 : 甲状腺疾患 : 診断と治療の進歩. 日本内科学会誌 99 : 683-685, 2010.
2) 米田誠, 松永晶子 : 橋本脳症, 特集 : 内科診療に潜む脳炎・脳症. 日本内科学会誌 106 : 1550-1554, 2017.
3) Matsunaga A, Ikawa M, Fujii A, et al : Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol 69 (1) : 14-20, 2013.
4) Kishitani T, Matsunaga A, Ikawa M, et al : Limbic encephalitis associated with anti-NH2-terminal of α-enolase antibodies : A clinical subtype of Hashimoto's encephalopathy. Medicine 96 (10) : e6181, 2017.
5) Fujii A, Yoneda M, Ito T, et al : Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunology 162 (1-2) : 130-136, 2005.
6) Yoneda M, Fujii A, Ito A, et al : High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. J Neuroimmunol 185 (1-2) : 195-200, 2007.
7) Wes(TM) (ウエス) 製品カタログ (プロテインシンプル ジャパン株式会社).

【Health Care】

P.990 掲載の参考文献
1) Bauer BA, Tilburt JC, Sood A, et al : Complementary and alternative medicine therapies for chronic pain. Chin J Integr Med 22 (6) : 403-411, 2016.
2) Bao Y, Kong X, Yang L, et al : Complementary and alternative medicine for cancer pain : an overview of systematic reviews. Evid Based Complement Alternat Med 2014. doi : 10.1155/2014/170396 [最終アクセス 2021年6月23日]
3) Alraek T, Lee MS, Choi TY, et al : Complementary and alternative medicine for patients with chronic fatigue syndrome : a systematic review. BMC Complement Altern Med 11 (1) : 87, 2011. doi : 10.1186/1472-6882-11-87 [最終アクセス 2021年6月23日]
4) 大西和子, 辻川真弓, 吉田和枝, 他 : 看護技術としての補完療法活用. 三重看護学誌 12 (1) : 1-6, 2010.
5) Things To Know About Massage Therapy for Health Purposes. National Center for Complementary and Integrative Health. https://www.nccih.nih.gov/health/tips/things-toknow-about-massage-therapy-for-health-purposes [最終アクセス 2021年6月19日]
6) Bervoets DC, Luijsterburg PA, Alessie JJ, et al : Massage therapy has short-term benefits for people with common musculoskeletal disorders compared to no treatment : A systematic review. J Physiother 61 : 106-116, 2015.
7) 柳井久江 : 4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
8) Priscilla K, Jayavanth Santha N, Priscilla K : Massage therapy-complementary and alternative therapeutic approach. Asian J Nurs Educ Res 4 : 516-519, 2014.
9) Kuge H, Mori H, Tanaka TH, et al : Difference between the effects of one-site and three-site abdominal hot-stone stimulation on the skin-temperature changes of the lower limbs. J Integr Med 11 : 314-319, 2013.
10) 森英俊, 大沢秀雄, 久下浩史, 他 : 鍼灸, あん摩マッサージ指圧刺激がサーモグラム・心拍変動・瞬時心拍数・瞳孔反応におよぼす効果. 筑波技術大学テクノレポート 22 (1) : 115-118, 2014.

最近チェックした商品履歴

Loading...